Brenus Pharma announces its international Scientific Committee
7.6.2023 19:00:00 EEST | Business Wire | Press release
Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee.
This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer.
The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field:
Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board
Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active member. Expertise in new drugs development.
Pr Alexander EGGERMONT MD, PhD. Pr of Oncology – Head of Clinical & Translational Immunotherapies. UMC 4, Utrecht (NL); Chief Scientific Officer. Pediatric oncology center Princessa Maxima, Utrecht. (NL)
Pr. Antoine ITALIANO MD, PhD. Pr of Oncology – Head of Early-phase trials units; Head of Precision medicine new program. Gustave Roussy, Cancer Campus Grand Paris (FR) ; Bergnonié Institute, UNICANCER Nouvelle-Aquitaine, Bordeaux. (FR)
Pr. Ignacio MELERO MD, PhD. Pr of Immunology – Head of translational immunotherapy research. CIMA 5, Navarra. (SP)
Pr Marck YARCHOAN MD. Associate Pr. of Medical Oncology at The Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins, Baltimore. (USA)
“Brenus is honored to have support & guidance of such professionals in the field. Their expertise will be instrumental in driving the first-in-human study forward and advancing the company’s mission to change a paradigm in oncology.” Benoit PINTEUR, Co-founder & CSO.
ABOUT BRENUS
Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment. Brenus has developed STC (Stimulated Tumor Cells), a technology platform mimicking relapsing conditions and enabling the education of patients' immune system, to fight against the resistance mechanisms of tumor cells.
For further information: www.brenus-pharma.com
____________________________
1 « Efficacy of STC-1010, a new allogeneic cancer vaccine in colorectal cancer models”
J Clin Oncol 41, 2023 (suppl 16; abstr e14661).
2 Centre de lutte contre le cancer Georges François Lecrec
3 European Society for Medical Oncology
4 University MC
5 Centro de Investigation Medical Aplicada
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005688/en/
Contact information
CONTACT BRENUS
Marion Brun
Communication Manager
contact@brenus-pharma.com
+ 33 (0)7 87 76 87 72
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HY10 Selected Among the First Participants for Visa’s Infinite Private Program14.7.2026 22:46:00 EEST | Press release
HY10, the first financial and lifestyle platform built for globally mobile ultra and high-net-worth individuals, today announced it is among the first businesses selected to participate in Visa's Infinite Private program. Unveiled at the Visa Payments Forum (VPF) in Paris, the launch brings together unlimited-spend payment cards, concierge and lifestyle services into a single integrated platform, powered by Visa's trusted global payments network. The announcement comes as more than 2,000 leaders from banks, fintechs and payment providers gather at Visa Payments Forum to explore the future of commerce and premium financial services. HY10's participation underscores its position at the forefront of premium financial experiences for globally mobile entrepreneurs, investors and families. "Private banking hasn't fundamentally evolved for decades," said Erekle Tokhosashvili, Co-Founder of HY10. "The world's wealthiest individuals are still forced to piece together multiple providers for bank
L&T Technology Services Partners with Anthropic to Deliver AI-Powered Engineering Intelligence for Products and Manufacturing14.7.2026 18:28:00 EEST | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced a partnership with Anthropic to accelerate Engineering Intelligence by integrating Claude models across engineering processes and LTTS’ AI-powered platforms. The collaboration will help LTTS’ enterprise clients redesign how products and software are developed, enabling faster innovation and improved outcomes at scale. Leveraging Claude across the engineering lifecycle and uniting deep engineering expertise, advanced AI and domain knowledge, LTTS’ Engineering Intelligence discipline will enable clients to create greater value. Rather than automating individual tasks, it enables teams to make faster decisions, streamline workflows and continuously improve how products, manufacturing plants and industrial systems are designed, built and maintained. By integrating Claude models into its platforms including AgenticIQ, PlxAI, Ainfonix™, A
Presidio Investors Announces Sale of ElevATE Semiconductor to Diodes Incorporated14.7.2026 17:56:00 EEST | Press release
Presidio Investors (“Presidio”), a lower middle market private equity firm, today announced that it has entered into a definitive agreement to sell ElevATE Semiconductor, Inc. (“ElevATE”) to Diodes Incorporated (Nasdaq: DIOD) in an all-cash transaction valued at $250 million. ElevATE, headquartered in San Diego, California, is a leading fabless designer of low-power, high-density integrated circuits for the automated test equipment (ATE) industry. The sale marks the successful realization of Presidio’s first continuation fund, which was formed in 2023 to extend the firm’s partnership with ElevATE and support the company’s next phase of growth. The acquisition of ElevATE by a leading global semiconductor company validates the strategy behind the continuation vehicle and delivers a strong outcome for the company, its employees, and Presidio’s investors. Presidio first invested in ElevATE in 2018, when the company was a small, founder-led team of analog chip designers serving the ATE mark
Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition to make EAA AirVenture show debut14.7.2026 17:30:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition are heading to the 2026 Experimental Aircraft Association (EAA) AirVenture in Oshkosh, Wisconsin. Both aircraft will be on display for the first time at the show alongside a broad lineup of Cessna and Beechcraft aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714774354/en/ Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition to make EAA AirVenture show debut “EAA AirVenture is one of the most important opportunities each year for us to connect with customers and the broader aviation community,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “Being on the ground in Oshkosh allows us to showcase the breadth of our portfolio. Events like AirVenture also give us valuable face-to-face time to better understand how our customers operate and
Clearlake Capital Announces Partnership with Databricks to Advance AI-Enabled Investing and Portfolio Value Creation14.7.2026 17:00:00 EEST | Press release
Clearlake Capital Group, L.P. ("Clearlake"), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced a partnership with Databricks, the Data and AI company, and West Monroe, a global business and technology consulting firm, to accelerate Clearlake’s portfolio companies’ adoption of data, analytics, and AI capabilities. Through the collaboration, Clearlake aims to connect investment, operational, financial, and portfolio data in a secure and scalable environment that accelerates enterprise-wide adoption of AI, drives productivity, and delivers measurable outcomes across the investment lifecycle from deal origination and due diligence to portfolio monitoring and value creation. By pairing cutting-edge technology with deep operational support, the partnership endeavors to help Clearlake’s portfolio companies stay ahead of industry disruption and build durable competitive advantage. “Data and A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom